Vutrisiran can improve and maintain functional capacity and quality of life in patients with transthyretin amyloidosis with ...

Alnylam Pharma has been riding high since revealing top-line results from its HELIOS-B trial of vutrisiran in transthyretin-mediated amyloidosis (ATTR) – but a look at the full data seems to ...

The announcement of top-line data from the HELIOS-B study sparked a 36% increase in Alnyam’s share price in pre-market trading as investors looked forward to a new revenue stream for the drug ...